Based on our Pharmacor Multiple Sclerosis advisory service, Decision Resources is offering an exclusive analyst call entitled Merck Serono Abandons Oral Cladribine: What Impact Will Its Termination Have on the Multiple Sclerosis Drug Market?

Based on our Pharmacor Multiple Sclerosis advisory service, Decision Resources is offering an exclusive analyst call entitled Merck Serono Abandons Oral Cladribine: What Impact Will Its Termination Have on the Multiple Sclerosis Drug Market?

Date & Time
Recorded live on Wednesday, July 6, 2011

This 15-minute analyst call, presented by Decision Resources Senior Analyst Jonathan W. Searles, will answer the following questions:

• What impact will oral cladribine's discontinuation have on the overall MS market?
• How will oral cladribine's discontinuation affect the uptake of current therapies, including Novartis/Mitsubishi Tanabe Pharma's Gilenya (the first oral disease-modifying therapy to launch in the major markets) and emerging agents in the late-stage pipeline?
• In light of the absence of oral cladribine, what will the future MS treatment algorithm look like as a result of the shifting dynamics between the current mainstays of treatment and novel agents?

This analyst call was held on July 6, 2011. Contact us to learn how you can purchase this service and access the recorded event.

Click here to view the invite.